安圖生物(603658.SH)擬出售參股公司Mobidiag全部股權
格隆匯4月8日丨安圖生物(603658.SH)公佈,2021年4月8日,公司參股公司芬蘭Mobidiag Oy(以下簡稱“Mobidiag”)股東與美國Hologic,Inc.(以下簡稱“Hologic”)簽署股權出售協議,計劃將其全部股份出售給Hologic,其中安圖生物持有Mobidiag 7.63%的股權以約4609萬歐元出售。
本次交易不會對公司淨利潤產生影響,獲得收益將直接計入公司留存收益,增加公司淨資產。本次交易完成後,公司不再持有Mobidiag股權。本次交易將增加公司現金流入,增強公司的持續經營能力,提高股東的投資回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.